Moderna is most shorted stock in S&P 500 as Americans skip jabs
Maker of Covid-19 shots has slumped since pandemic as people turn against vaccines
Related reading
US vaccine overhaul unnerves investors as sceptics seize advisory posts
Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments
America’s unfortunate backward step on vaccines
2025 has been a good year for immunisation science, but not in the US
Trump administration reverses move to block Moderna flu vaccine trial
U-turn comes after backlash from the company and US biotech industry
A test for global public health
The decline in funding for vaccinations poses a worldwide threat
How US anti-vaxxers found they were not immune to pushback
Recent setbacks for the movement signal a potential turning point for the vaccine makers as the market picks up
Measles surging again as vaccine rates drop, WHO warns
Immunisation has helped cut global cases by 71% since 2000 but progress is slowing